AGFA HealthCare
AGFA HealthCare's Enterprise Imaging advancements and innovations enhance the delivery of patient care and promote clinician wellbeing by increasing the efficiency of radiologists' workflow
MORTSEL, BELGIUM / ACCESSWIRE / May 8, 2024 / AGFA HealthCare's Enterprise Imaging Platform offers near-real-time access to images, powerful diagnostic and Artificial Intelligence tools, smart workflows that enable seamless sharing between sites, enhanced collaboration and more. Radiologists can increase their productivity and wellbeing while focusing on what's most important - diagnosing and treating patients, and a "life in flow."
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.At UKIO 2024, AGFA HealthCare will demonstrate how its commitment to delivering "any image anywhere, any time" increases the day-to-day performance and job satisfaction of radiologists, radiographers and clinical teams. By harnessing the power of today's technology, AGFA HealthCare Enterprise Imaging creates a unified Imaging Health Record™ (IHR) that supports healthcare institutions to achieve their organisational goals, enabling clinical collaboration to support the patient pathway and empowering radiologists to meet their daily challenges.
"In today's world, enabling patient and clinician wellbeing depends on finding the ‘sweet spot' where patient care and technology intersect. By empowering radiologists and radiographers with tools and workflows that cut through the noise, we help them stay focused on patient care and making confident diagnoses, while supporting their own work/life balance. Our vision is to provide innovative technology that feels like an extension of their thought processes, bringing them to that moment at work when distractions fade away, they are at one with the technology, and everything just works," says Roberto Anello, Regional President for Northern Europe at AGFA HealthCare.
Enhanced productivity and wellbeing
At UKIO 2024, visitors can discover how the right solutions can help redefine the radiologist's flow by increasing the efficiency of their workflow, enhancing their productivity, and boosting the value of their work:
- The power of Streaming: The explosion in medical imaging data requires solutions that make critical information readily available, regardless of location and time. Web-based streaming technology makes images available in seconds, wherever they are needed. Radiologists break free from geographical constraints, and all members of the care team are empowered to collaborate seamlessly.
- Leveraging the benefits of Cloud: Enterprise Imaging Cloud seamlessly closes the image management infrastructure gap, delivering a Software-as-a-Service (SaaS) solution that is secure, scalable, and accessible; easy to maintain and use; at a predictable cost.
- Teach & Research and Peer Learning: Carefully crafted modules let you turn the radiology department into a continuous learning environment that plays its role in facilitating scientific research, clinical trials, collaboration with AI vendors and more.
- RUBEE® AI packages: AGFA HealthCare's expanded portfolio of curated AI packages demonstrates the power of embedding AI into Enterprise Imaging workflows. Discover how our customers are leveraging these innovations in their daily practice and becoming more productive.
- Connecting partners in healthcare: Enterprise Imaging Cloud facilitates the creation of an Imaging Health Network™ (IHN), which makes images available to all members of the care team, at all times, no matter where they are located, including on compatible mobile devices.
- Don't forget to engage with our Subject Matter Experts during the event. We are offering a series of insight sessions at our booth, all led by our regional Enterprise Imaging pioneers.
- "Novel Methods for Image Access and Workflow Sharing across UK Imaging Networks" will be presented by Paige Miller, Pre-Sales Consultant.
- "A novel Peer Learning tool to support and supervise clinical reporters; REALM and Candour as part of good radiology service governance" will be delivered by Dr. Nick Spencer, Chief Clinical Information Officer.
- "New Technology for Image Distribution and Reporting" will be hosted by Lee Storey, Support & Managed Services Manager.
Session timings will be announced in the coming weeks - bookmark our News section to be kept up to date on more information.
Reach out to us at UKIO 2024 to see how to bring flow to your health organization - June 10-12, 2024, ACC Liverpool, booth #B23
About AGFA HealthCare
At AGFA HealthCare, we are transforming the delivery of care - supporting healthcare professionals across the globe with secure, effective, and sustainable imaging data management. As a company, we are dedicated to our customers, and we have harnessed a value framework of Mission, Vision and Customer Delivery Principles into our routine operations. Through these principles, we commit a consistent high-yield code of conduct to our associates - channelling our experience and aspirations to all of our stakeholders. Our Empowerer profile supports our focus on creating an exceptional experience through the power of technology and is an integral foundation to our company standards. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.
AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. Imaging Health Network is a trademark and RUBEE is a registered trademark of AGFA HealthCare N.V. All rights reserved. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.
Contact Information:
Buse Kayar
buse.kayar@issuerdirect.com
SOURCE: AGFA Healthcare
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
